Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Sold Sen. Cory A. Booker

Senator Cory A. Booker (Democratic-New Jersey) recently sold shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). In a filing disclosed on September 09th, the Senator disclosed that they had sold between $1,001 and $15,000 in Alnylam Pharmaceuticals stock on August 11th.

Senator Cory A. Booker also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Netflix (NASDAQ:NFLX) on 8/11/2026.
• Sold $15,001 – $50,000 in shares of McDonald’s (NYSE:MCD) on 8/11/2026.
• Sold $15,001 – $50,000 in shares of NVIDIA (NASDAQ:NVDA) on 8/11/2026.
• Sold $1,001 – $15,000 in shares of JD.com (NASDAQ:JD) on 8/11/2026.
• Sold $100,001 – $250,000 in shares of Amazon.com (NASDAQ:AMZN) on 8/11/2026.

Alnylam Pharmaceuticals Stock Up 0.5%

ALNY opened at $248.68 on Friday. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals, Inc. has a 1-year low of $197.81 and a 1-year high of $495.55. The company has a market capitalization of $33.28 billion, a PE ratio of 46.22 and a beta of 0.31. The firm’s 50 day simple moving average is $254.43 and its two-hundred day simple moving average is $288.99.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. The firm had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.32 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The company’s revenue for the quarter was up 66.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.51) EPS. As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.71 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Brighton Jones LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $243,000. Geneos Wealth Management Inc. boosted its position in Alnylam Pharmaceuticals by 372.3% during the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 175 shares in the last quarter. Flow Traders U.S. LLC purchased a new position in Alnylam Pharmaceuticals during the second quarter worth approximately $241,000. Daiwa Securities Group Inc. grew its holdings in Alnylam Pharmaceuticals by 0.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after purchasing an additional 35 shares during the period. Finally, NewEdge Advisors LLC grew its holdings in Alnylam Pharmaceuticals by 70,300.0% in the second quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company’s stock valued at $229,000 after purchasing an additional 703 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analyst Ratings Changes

ALNY has been the subject of several research reports. BMO Capital Markets reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, August 31st. Royal Bank Of Canada cut their price target on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating on the stock in a research report on Friday, July 31st. Wall Street Zen cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 2nd. TD Cowen restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, August 31st. Finally, Raymond James Financial raised Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 target price on the stock in a report on Monday, August 3rd. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $376.67.

About Senator Booker

Cory Booker (Democratic Party) is a member of the U.S. Senate from New Jersey. He assumed office on October 31, 2013. His current term ends on January 3, 2027. Booker (Democratic Party) ran for re-election to the U.S. Senate to represent New Jersey. He won in the general election on November 3, 2020. Booker also ran for election for President of the United States. He did not appear on the ballot for the Democratic convention on August 18, 2020. Booker announced that he was running for president of the United States on February 1, 2019. He suspended his presidential campaign on January 13, 2020. Before being elected to the Senate, Booker served as the 36th mayor of Newark. He also served on the Newark City Council for the Central Ward. In September 2017, he was rated the third most liberal senator based on his voting record, according to The New York Times. Booker was born in 1969 in Washington, D.C., and grew up in Harrington Park, New Jersey. He attended Stanford University on a varsity football scholarship, receiving a B.A. in 1991 and an M.A. in 1992. Booker was a Rhodes Scholar at the University of Oxford, where he earned a graduate degree in history in 1994. He then attended Yale Law School, graduating with a J.D. in 1997. After completing his education, Booker moved into a public housing project in Newark, New Jersey, became a tenant organizer, and founded a nonprofit that provided legal assistance to low-income families. He was elected to the Newark City Council in 1998 and served there until 2002, when he ran unsuccessfully for mayor. The same year, he became a partner at Booker, Rabinowitz, Trenk, Lubetkin, Tully, DiPasquale & Webster. In 2006, Booker ran again for mayor of Newark and was elected with 72% of the vote. He served as mayor until 2013. On October 16, 2013, Booker won a special election to the U.S. Senate after the death of Sen. Frank Lautenberg (D). Booker was re-elected to the U.S. Senate on November 4, 2014. In 2016, Booker published a memoir titled United: Thoughts on Finding Common Ground and Advancing the Common Good.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).